NCT Number: NCT02489786
A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital
Digoxin is the primary cardiac glycoside in clinical use. Because of the narrow therapeutic index and risk of toxicity, therapeutic drug monitoring is highly recommended. In Egypt, most cardiologists give digoxin holiday for both atrial fibrillation and heart failure, it is not clear if the interrupted digoxin regimens are effective since serum digoxin concentrations might fall below the therapeutic range.
Objective: To evaluate and compare the digoxin serum concentration and patient's quality of life in the continuous versus interrupted digoxin dosing regimens.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
About this study
Digoxin is a cardiac glycoside prescribed in heart failure and certain supraventricular tachyarrhythmias. It exerts a positive inotropic, neurohormonal, and electro physiologic actions on the heart . For heart failure patients, the targeted steady state serum digoxin level is between 0.5 and 0.8 ng/ml . Ventricular rate control in atrial fibrillation patients will usually require higher digoxin steady state serum concentrations . However, serum digoxin level higher than 2 ng/ml is associated with increased incidence of adverse drug reactions and should be avoided . Because of inter and intra-patient variability, narrow therapeutic index, and risk of toxicity, digoxin doses are calculated based on the patient weight, renal status, indications and drug interactions. Due to substantial overlap between therapeutic and toxic levels of digoxin, therapeutic drug monitoring is a must especially in patients with deteriorating renal function and electrolyte disturbance. In Egypt, most cardiologists give a digoxin holiday for patients with atrial fibrillation and /or heart failure where patients skip the drug doses on Thursday and Friday or Friday only every week to avoid possible drug accumulation and toxicity. It is not clear if these interrupted digoxin regimens really offer safer alternative over the continuous dosing regimens without compromising the effectiveness. It is anticipated that plasma digoxin levels may fall below the therapeutic range during the holiday which may affect patient clinical status and quality of life.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with atrial fibrillation (AF)
- with or without congestive heart failure (CHF)
- taking digoxin tablets with or without holiday regimens
Exclusion criteria
- taking the following drugs concurrently: amiodarone, verapamil, quinidine and propafenone.
- diagnosed with thyroid disorders (hyperthyroidism & hypothyroidism).
- diagnosed with renal failure
- pregnant
Treatment and study plan
patients take 0.25 mg of digoxin daily except thursday and friday
Drugpatients take 0.125 mg of digoxin daily
Drugdigoxin dose is calculated using Jusko-Koup method and given daily
DrugPrimary outcomes
-
measuring digoxin trough steady state plasma concentrations for the interrupted and continuous treatment regimens
Time frame: 1 month
Secondary outcomes
-
evaluating patients quality of life using quality of life questionnaire for atrial fibrillation patients
Time frame: 1 month
-
evaluating signs and symptoms of digoxin side effects and toxicity by using specific structured questions
Time frame: 1 month
Sponsors and collaborators
Lead sponsor
Cairo University
Other
Registry information
Official study title
A Prospective Randomized Study of Different Digoxin Treatment Regimens in Egyptian Hospital
Important dates
- Study start
- 2012
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Jul 3, 2015
- Registry last updated
- Jul 7, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination
NCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial DetailsEffect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling
NCT05993897
Arrhythmias, Cardiac, Atrial Fibrillation
Aswān, Aswan Governorate, Egypt
View Trial DetailsA Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
NCT05357690
Arrhythmias, Cardiac, Atrial Fibrillation
Rochester, Minnesota, United States
View Trial DetailsThe Norwegian Exercise in Atrial Fibrillation Trial
NCT05164718
Arrhythmias, Cardiac, Atrial Fibrillation
Drammen, Norway
View Trial Details